Skip to main content

Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM

Publication ,  Journal Article
Sampson, JH; Archer, GE; Bigner, DD; Davis, T; Friedman, HS; Keler, T; Mitchell, DA; Reardon, DA; Sawaya, R; Heimberger, AB
Published in: Journal of Clinical Oncology
May 20, 2008

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

2011 / 2011

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sampson, J. H., Archer, G. E., Bigner, D. D., Davis, T., Friedman, H. S., Keler, T., … Heimberger, A. B. (2008). Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology, 26(15_suppl), 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011
Sampson, J. H., G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, and A. B. Heimberger. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011.
Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2011–2011.
Sampson, J. H., et al. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2011–2011. Crossref, doi:10.1200/jco.2008.26.15_suppl.2011.
Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2011–2011.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

2011 / 2011

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences